- Home
- DRDB vs MRVI Comparison
DRDB vs MRVI Comparison
Compare DRDB & MRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DRDB
- MRVI
- Stock Information
- Founded
- DRDB 2024
- MRVI 2014
- Country
- DRDB United States
- MRVI United States
- Employees
- DRDB N/A
- MRVI 560
- Industry
- DRDB
- MRVI Biotechnology: Pharmaceutical Preparations
- Sector
- DRDB
- MRVI Health Care
- Exchange
- DRDB Nasdaq
- MRVI Nasdaq
- Market Cap
- DRDB 315.3M
- MRVI 350.1M
- IPO Year
- DRDB 2024
- MRVI 2020
- Fundamental
- Price
- DRDB $10.28
- MRVI $2.42
- Analyst Decision
- DRDB
- MRVI Hold
- Analyst Count
- DRDB 0
- MRVI 10
- Target Price
- DRDB N/A
- MRVI $5.84
- AVG Volume (30 Days)
- DRDB 91.6K
- MRVI 1.5M
- Earning Date
- DRDB 01-01-0001
- MRVI 08-11-2025
- Dividend Yield
- DRDB N/A
- MRVI N/A
- EPS Growth
- DRDB N/A
- MRVI N/A
- EPS
- DRDB N/A
- MRVI N/A
- Revenue
- DRDB N/A
- MRVI $219,830,000.00
- Revenue This Year
- DRDB N/A
- MRVI N/A
- Revenue Next Year
- DRDB N/A
- MRVI $7.23
- P/E Ratio
- DRDB $587.54
- MRVI N/A
- Revenue Growth
- DRDB N/A
- MRVI N/A
- 52 Week Low
- DRDB $9.87
- MRVI $1.67
- 52 Week High
- DRDB $10.43
- MRVI $9.60
- Technical
- Relative Strength Index (RSI)
- DRDB N/A
- MRVI 49.60
- Support Level
- DRDB N/A
- MRVI $2.28
- Resistance Level
- DRDB N/A
- MRVI $2.47
- Average True Range (ATR)
- DRDB 0.00
- MRVI 0.14
- MACD
- DRDB 0.00
- MRVI -0.01
- Stochastic Oscillator
- DRDB 0.00
- MRVI 27.45
About DRDB Roman DBDR Acquisition Corp. II Ordinary shares
Roman DBDR Acquisition Corp II is a blank check company.
About MRVI Maravai LifeSciences Holdings Inc.
Maravai LifeSciences Holdings Inc is a life sciences company that provides critical products that drive the development of groundbreaking vaccines, drug therapies, cell and gene therapies, and diagnostics. The group's solutions empower research into human diseases and support the entire biopharmaceutical development process from early discovery to commercialization. Its reportable segments are Nucleic acid production and biologics safety testing. It generates a majority of its revenue from Nucleic Acid Production and focuses on the manufacturing and sale of nucleic acid products to support the needs of customers' research, and therapeutic and vaccine programs. In addition, the segment also provides research products for labeling and detecting proteins in cells and tissue samples.